Loading
USP7 (Ubiquitin C-terminal hydrolase 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Burkitt lymphoma.
Hydrolase that deubiquitinates target proteins such as ARMC5, FOXO4, DEPTOR, KAT5, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, PTEN, KMT2E/MLL5 and DAXX. Together with DAXX, prevents MDM2 self-ubiquitination and enhances the E3 ligase activity of MDM2 towards p53/TP53, thereby promoting p53/TP53 ubiquitination and proteasomal degradation. Deubiquitinates p53/TP53, preventing degradation of p53/TP53, and enhances p53/TP53-dependent transcription regulation, cell growth repression and apoptosis.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Burkitt Lymphoma, Plasma Cell Myeloma.
In plain words · USP7 (Ubiquitin C-terminal hydrolase 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Burkitt lymphoma.
USP7 (Ubiquitin C-terminal hydrolase 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Burkitt lymphoma.
Hydrolase that deubiquitinates target proteins such as ARMC5, FOXO4, DEPTOR, KAT5, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, PTEN, KMT2E/MLL5 and DAXX.
No product in this corpus aims at USP7 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA USP7: RNA low tissue specificity; no normal tissue stained high; highest cancer staining testis cancer (4 of 10 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q93009; CIViC gene USP7; IntOGen USP7; Human Protein Atlas USP7 tissue; Open Targets ENSG00000187555 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Everett R.D. et al, EMBO J, 1997, "A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein". Source.
Sources: HGNC HGNC:12630 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q93009 (protein name, function text, keywords and locations (REST API)); CIViC gene USP7 (1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0)); IntOGen USP7 (driver in 2 cohorts (Act 0, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Hydrolase that deubiquitinates target proteins such as ARMC5, FOXO4, DEPTOR, KAT5, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, PTEN, KMT2E/MLL5 and DAXX. Together with DAXX, prevents MDM2 self-ubiquitination and enhances the E3 ligase activity of MDM2 towards p53/TP53, thereby promoting p53/TP53 ubiquitination and proteasomal degradation. Deubiquitinates p53/TP53, preventing degradation of p53/TP53, and enhances p53/TP53-dependent transcription regulation, cell growth repression and apoptosis. Deubiquitinates p53/TP53 and MDM2 and strongly stabilises p53/TP53 even in the presence of excess MDM2, and also induces p53/TP53-dependent cell growth repression and apoptosis. Deubiquitination of FOXO4 in presence of hydrogen peroxide is not dependent on p53/TP53 and inhibits FOXO4-induced transcriptional activity. In association with DAXX, is involved in the deubiquitination and translocation of PTEN from the nucleus to the cytoplasm, both processes that are counteracted by PML. Location: Nucleus; Cytoplasm; Nucleus, PML body; Chromosome (UniProt). Locus 16p13.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high; medium in Adrenal gland, Appendix, Bronchus, Caudate, Cerebellum, Cerebral cortex and more.
Medium only: breast cancer, carcinoid, colorectal cancer, endometrial cancer.
HPA USP7 tissue · HPA USP7 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"USP7" OR ABSTRACT:"USP7" OR TITLE:"ubiquitin specific peptidase 7" OR ABSTRACT:"ubiquitin specific peptidase 7" OR TITLE:"Ubiquitin C-terminal hydrolase 7" OR ABSTRACT:"Ubiquitin C-terminal hydrolase 7" OR TITLE:"HAUSP" OR ABSTRACT:"HAUSP") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about USP7, not a curated reading list.
Shares Burkitt lymphoma, CIViC, IntOGen, Multiple myeloma.
Shares Burkitt lymphoma, CIViC, IntOGen.
Shares Burkitt lymphoma, CIViC, IntOGen.
Shares Burkitt lymphoma, CIViC, IntOGen.
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.